- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Diagnosis of Intestinal Parasites
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antidepressants, With Confirmation, Urine
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Maternal Serum AFPTest code(s) 5059
Question 1. My patient had a negative maternal serum AFP screen. What should I do next?
A negative screen means it is unlikely the fetus has an open neural tube defect. But a negative screen does not guarantee the birth of a healthy baby. The single AFP marker is not recommended as a screening tool for Down syndrome and other chromosomal abnormalities. If the patient has undergone a chorionic villus sampling (CVS) and had a normal chromosome analysis test result, no additional follow up testing for Down syndrome is needed. Similarly, if the patient has had a negative result on a first-trimester maternal serum screen or a noninvasive prenatal screen (NIPS) during this pregnancy, no follow-up testing is needed for Down syndrome. If not, it is standard practice to offer a second trimester maternal serum screen that includes markers for Down syndrome and trisomy 18.1 Second trimester screening options include the Quad Screen (test code 30294) or Penta Screen (test code 15934), and/or noninvasive prenatal screening (NIPS; test code 92777 or 91933[NY]). Please contact Quest Genomics Client Services at 866-GENE-INFO to discuss the case with a genetic counselor.
Question 2. My patient’s result was screen positive for an open neural tube defect (ONTD). What should I do next?
A positive ONTD screen result means there is an increased risk for the fetus to be affected with a neural tube defect or other congenital abnormality. If the patient’s AFP is less than 3.5 multiple of median (MoM), if ultrasound dating confirms the gestational age and a singleton pregnancy, and if the gestational age is less than 18 weeks, testing a newly collected sample can be considered. If this second sample confirms an elevated AFP MoM or if a second AFP test is not performed, genetic counseling, ultrasound examination, and possible amniocentesis would be appropriate.
Note that underestimation of gestational age is one of the most frequent causes of an elevated AFP MoM.
Question 3. The report indicates a different gestational age than what I determined. How is the reported gestational age calculated?
The gestational age is derived from the estimated date of delivery (EDD) and the collection date provided; it is an exact calculation by calendar days. Gestational wheels may be inaccurate by several days or more.
Note that the gestational age is reported in decimal weeks. For example, 15 weeks 4 days is reported as 15.6 weeks.
Question 4. When is it appropriate to change the gestational age or estimated date of delivery (EDD) on a maternal serum screen report?
It’s appropriate to change the gestational age or EDD when the data used for screening are substantially above or below that determined by ultrasound.
The earliest EDD calculated by ultrasound should be used for dating purposes.2 An ultrasound derived EDD is most accurate when determined in the first trimester. Accuracy decreases with advancing gestational age. For example, accuracy of an ultrasound EDD is ±7 days in the first trimester and ±10 days in the second trimester.
If a first trimester ultrasound EDD is available and the gestational age used for screening is within the EDD ±7 days, the gestational age should not be changed for screening purposes. Similarly, if second trimester (but not first trimester) EDD is available and the gestational age used for screening is within the EDD ±10 day range, the gestational age should not be changed for screening purposes. If the gestational age used for screening is outside the ultrasound EDD range, it may be appropriate to change the gestational age used for screening.
If you want to change the EDD/gestational age used for a specific patient’s screening test, please contact your local Quest Diagnostics laboratory or call Quest Genomics Client Services at 866-GENE-INFO. If the revised gestational age is between 15.0 to 22.9 weeks gestation, we can calculate and report a new NTD risk. If the revised gestational age is <15.0 weeks, we cannot calculate a new risk. Consider submitting a second specimen for screening, collected when the patient is between 15.0 to 22.9 weeks gestation (preferably 16 to 18 weeks). If the revised gestational age is >22.9 weeks gestation, we cannot calculate a new NTD risk, and a more accurate risk assessment cannot be provided.
Question 5. Why is there no NTD risk reported for samples collected during 14.0 - 14.9 weeks’ gestation?
The NTD detection rate is significantly lower at 14.0 to 14.9 weeks’ gestation than at 15.0 to 22.9 weeks’ gestation. Therefore, samples collected during the 14th week of gestation with an AFP value below 2.5 MoM (single gestation, nondiabetic) will be reported as screen negative without a patient-specific risk. For optimal NTD screening, collect samples when the patient is at 16 to 18 weeks’ gestation.
Question 6. Why is there no numerical NTD risk reported for women carrying twins or triplets?
AFP concentrations seen in NTD-affected and unaffected singleton pregnancies are well known. Therefore, an adjusted AFP MoM can be used to calculate an NTD risk in singleton pregnancies. AFP concentration data are insufficient, however, to allow similar calculations for twin and triplet pregnancies. Nevertheless, twin and triplet pregnancies can still be interpreted as screen positive or screen negative based on the AFP MoM.
Question 7. My patient has a family history of neural tube defect (NTD). What impact does this have on her NTD screen results?
Please call Quest Genomics Client Services at 866-GENE-INFO to discuss this case with a genetic counselor. Documentation of the abnormality in the family may enable a more specific risk assessment or indicate whether additional studies should be performed.
Question 8. Besides an open neural tube defect (ONTD), what else can cause an elevated AFP screen result?
Elevated AFP screen results have been associated with pregnancy complications including fetal ventral wall defects (VWD) and other fetal anomalies, low birth weight, intrauterine growth retardation, preterm labor, preeclampsia, and fetal demise. If diagnostic testing is negative for ONTD, consider high risk prenatal care.
- Driscoll DA and Gross SJ for the Professional Practice Guidelines Committee. Screening for fetal aneuploidy and neural tube defects. Genet Med. 2009;11:818-821.
- American College of Obstetricians and Gynecology. Committee Opinion No 611: Method for estimating due date. Obstet Gynecol. 2014;124:863-866.